Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use

Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone

Administer 2 mL, dose intramuscular naloxone 0,8 mg

Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.

This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.